Thomas B. Smith Sells 9,593 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Collegium Pharmaceutical Trading Up 0.4 %

Collegium Pharmaceutical stock opened at $38.93 on Friday. Collegium Pharmaceutical, Inc. has a 52 week low of $20.95 and a 52 week high of $40.95. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.04 and a current ratio of 1.11. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of 16.22 and a beta of 0.94. The company has a 50 day moving average price of $35.94 and a 200 day moving average price of $35.46.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The company had revenue of $145.28 million during the quarter, compared to analyst estimates of $143.94 million. During the same quarter in the prior year, the company earned $1.13 earnings per share. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. Research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.82 EPS for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently bought and sold shares of the business. Caxton Associates LP purchased a new stake in shares of Collegium Pharmaceutical in the first quarter worth approximately $1,730,000. BNP Paribas Financial Markets increased its stake in Collegium Pharmaceutical by 119.6% in the 4th quarter. BNP Paribas Financial Markets now owns 146,543 shares of the specialty pharmaceutical company’s stock valued at $4,511,000 after buying an additional 79,823 shares during the period. Foundry Partners LLC purchased a new stake in Collegium Pharmaceutical in the 2nd quarter worth approximately $492,000. LSV Asset Management boosted its stake in shares of Collegium Pharmaceutical by 188.7% during the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after buying an additional 248,751 shares during the period. Finally, O Shaughnessy Asset Management LLC boosted its stake in shares of Collegium Pharmaceutical by 159.3% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 45,735 shares of the specialty pharmaceutical company’s stock valued at $1,775,000 after buying an additional 28,100 shares during the period.

Analyst Ratings Changes

Several equities analysts have recently weighed in on COLL shares. Truist Financial raised their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Piper Sandler reiterated a “neutral” rating and set a $37.00 price objective (down previously from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 31st. Finally, Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and upped their target price for the company from $41.00 to $44.00 in a report on Friday, June 7th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.